Gemcitabine Hydrochloride for Treating SARS-CoV-2

Gemcitabine Hydrochloride for Treating SARS-CoV-2

A 2′-deoxycytidine hydrochloride with geminal fluoro substituents is known as gemcitabine hydrochloride. It is a deoxycytidine analog that prevents the proliferation of various cell lines, including BxPC-3, Mia Paca-2, PANC-1, PL-45, and AsPC-1 cells. It also prevents DNA synthesis and repair. This substance has been used to treat a number of carcinomas, including non-small cell lung cancer, pancreatic cancer, bladder cancer, and breast cancer, as a ribonucleotide reductase inhibitor. According to studies, gemcitabine hydrochloride can be used to treat or prevent viral infections.

 

Repurposing currently available clinically tested medications with known safety profiles, availability, and cheaper cost is one practical and quick solution given the time and cost of developing innovative therapies. To prepare for potential future developing coronaviruses, a subset of medicines has been evaluated against SARS-CoV and MERS-CoV to discover medications with wide action against coronaviruses. Investigations have been done into how MERS-CoV or SARS-CoV respond to gemcitabine hydrochloride. Gemcitabine hydrochloride for SARS-CoV-2 has been shown to suppress MERS-CoV and SARS-CoV with micromolar EC50 and low toxicity.